Presented in part as ‘Carboplatin-Paclitaxel vs. Cisplatin-Paclitaxel and Update on GOG0182-ICON5’ 4th International Symposium, Advanced Ovarian Cancer: Optimal Therapy, Update. Valencia, Spain (28 February 03).
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
Article first published online: 11 DEC 2003
International Journal of Gynecological Cancer
Volume 13, Issue 6, pages 735–740, November 2003
How to Cite
Bookman, M. A., Greer, B. E. and Ozols, R. F. (2003), Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. International Journal of Gynecological Cancer, 13: 735–740. doi: 10.1111/j.1525-1438.2003.13602.x
- Issue published online: 11 DEC 2003
- Article first published online: 11 DEC 2003
- Accepted for publication September 1, 2003.
- ovarian cancer;
Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.